Drug intelligence / Profile preview

FP-10

Development stage: Phase 3
Administration: Oral

Overview

FP-10 is a food ingredient derived from milk casein. It is being investigated for its ability to inhibit *Helicobacter pylori* from attaching to the gastric epithelium and to decrease intragastric urease activity. It is hypothesized to increase the eradication rates of *H. pylori* when used in conjunction with a triple therapy regimen (proton pump inhibitor, amoxicillin, and clarithromycin).

Beyond the preview

Go deeper on FP-10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FP-10.

Explore the full profile